IRD Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.1M
+50.6%
755.0K
-65.0%
2.2M
-44.2%
3.9M
+25.5%
3.1M
Cost of Revenue
0
0
0
0
0
Gross Profit
1.1M
+50.6%
755.0K
-65.0%
2.2M
-44.2%
3.9M
+25.5%
3.1M
Operating Expenses
20.4M
+18.3%
17.2M
+4.3%
16.5M
+7.9%
15.3M
+34.5%
11.4M
R&D
14.5M
+29.3%
11.2M
+6.0%
10.6M
+1.4%
10.4M
+62.7%
6.4M
SG&A
5.9M
-2.3%
6.0M
+1.4%
5.9M
+21.6%
4.9M
-1.8%
5.0M
Operating Income
-19247000
-16.8%
-16480000
-14.7%
-14364000
-25.4%
-11453000
-37.8%
-8311000
EBITDA
-19225000
-16.8%
-16466000
-14.7%
-14351000
-25.4%
-11440000
-37.9%
-8298000
Net Income
-46495000
-474.2%
-8098000
+87.6%
-65535000
-296.6%
-16523000
+5.3%
-17454000
EPS (Basic)
$-0.46
-475.0%
$-0.08
+89.3%
$-0.75
-275.0%
$-0.20
+20.0%
$-0.25
EPS (Diluted)
$-0.46
-228.6%
$-0.14
+81.3%
$-0.75
-275.0%
$-0.20
+20.0%
$-0.25
Shares (Diluted)
101.8M
-8.6%
111.4M
+28.2%
86.9M
+7.3%
81.0M
+14.7%
70.6M
Opus Genetics (IRD) — Financials